Novo outlays $2.6bn in Hengrui deal to bolster oral obesity pipeline
Novo has inked a licensing agreement with Shanghai-based biopharma, Hengrui Pharma for an oral metabolic disease candidate as the pharma …
Post
-
-
MSD bets $2.13bn on SciBrunch’s KRAS (ON) inhibitor
MSD (Merck & Co) has once again turned to China to fortify its pipeline – this time inking a licensing …
-
AstraZeneca to invest $2bn in Summit for ADC combination therapies
AstraZeneca has agreed to invest $2bn in newly issued equity in Summit Therapeutics to develop combination therapies using the bispecific …
-
Tolerance Bio signs $560m worldwide TLB-33 deal with Tanabe Pharma
Tolerance Bio has signed an agreement securing an exclusive licence from Tanabe Pharma for TLB-33, a clinical-stage anti-IL-33 monoclonal antibody, …
-
Beyond OEB5: Is OEB6 really the next standard for high-potency pharma?
Few areas of pharmaceutical manufacturing have attracted as much investment in recent years as high-potency containment. The expansion of oncology pipelines …
-
AbbVie lands FDA approval for next-generation Parkinson’s drug, Juvmo
The US Food and Drug Administration (FDA) has approved AbbVie’s next generation dopamine-based Parkinson’s disease therapy, tavapadon – potentially validating …
-
Oral solid dose at a turning point: Scaling for the next generation of therapies
As the first oral GLP-1 receptor agonists launch in 2026, we are reminded yet again of the enduring importance of …
-
Novo inks $1.33bn long-lasting injectable pact with Sweden-based Nanexa
Novo has signed a license agreement with Nanexa to use the Swedish biotech’s longer-lasting drug delivery technology, as the company …
-
Daiichi Sankyo, MSD withdraw cancer drug application
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at …
-
Mirum and Incyte’s Atebrioz approved for FOP in US
The US Food and Drug Administration (FDA) has approved Mirum Pharmaceuticals and Incyte’s Atebrioz (zilurgisertib) for the treatment of fibrodysplasia …
-
China expands its manufacturing role for biopharma’s new drugs
Biopharma companies are increasingly choosing to manufacture their newer FDA-approved innovator and biosimilar products at facilities in China, signalling emerging …
-
Aptar Pharma and Macquarie University partner on drug delivery project
Aptar Pharma is collaborating with Macquarie University in a partnership that will see the drug delivery specialist and Australian institution …
-
FDA commissioner nominee affirms MMR vaccine safety despite Trump’s claims
Dr Heidi Overton, Donald Trump’s nominee to lead the US Food and Drug Administration (FDA), has affirmed the safety and …
-
Roche and Earendil forge $1.5bn bispecific discovery deal
Roche-owned Genentech has penned a blockbuster deal with Earendil Labs to discover and develop bispecific antibodies for oncology. In exchange for …
-
Amberstone and Henlius agree to develop solid-tumour T-cell engagers
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to …
